InsidersTradesSigma
Follow the 康华生物 stock price and the full directors' dealings record of the company, a listed equity based in China. Shares are listed on the CN market, under the supervision of SSE / SZSE (CSRC). Operating in the Health Care sector, 康华生物 has logged 12 public disclosures. Market capitalisation: €5.8bn. The latest transaction was disclosed on 21 November 2023 (Sale). Among the most active insiders: 三明玖日广隶商贸合伙企业(有限合伙). Every trade is openly available.
12
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€98m
12 ops.
Sell Volume
22Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 7,075 of 28,752 companies
64.2
score / 100
Value51
Quality77
FCF yld5.3%
Earn yld3.8%
EV/EBITDA17.5x
ROE6.4%
Gross mgn92%
Net mgn19%
Debt/EBITDA0.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 21 November 2023
Declarations12 total
425,635 sharesA股XSHESZSE:173000004751926200
425,635 sharesA股XSHESZSE:173000004751929250
425,635 sharesA股XSHESZSE:173000004751933100
425,635 sharesA股XSHESZSE:173000004751936500
425,635 sharesA股XSHESZSE:173000004751941820
425,635 sharesA股XSHESZSE:173000004751923070
12 of 12 declarations
About 康华生物
康华生物 is a company focused on the health and pharmaceutical sector, providing innovative solutions in biotechnology. It is listed on the XSHE market.